We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+30.1%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$393M
AUM Growth
+$6.69M
Cap. Flow
+$2.85M
Cap. Flow %
0.72%
Top 10 Hldgs %
57.16%
Holding
48
New
12
Increased
9
Reduced
16
Closed
1
Avg Time Held
4.1 quarters
Top 10 Avg Time Held
4.8 quarters
Top 20 Avg Time Held
5.1 quarters

Top Buys

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$5.39M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$4.61M
3
HROW icon
Harrow
HROW
+$4.38M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$3.44M
5
CLLS icon
Cellectis
CLLS
+$3.16M

Top Sells

Rank Stock Value
1
KYNB icon
Kyntra Bio
KYNB
+$9.86M
2
AXGN icon
Axogen
AXGN
+$6.11M
3
VKTX icon
Viking Therapeutics
VKTX
+$4.46M
4
BFRA
Biofrontera AG American Depositary Shares
BFRA
+$4.24M
5
BPMC icon
Blueprint Medicines
BPMC
+$3.48M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AXGN icon
1
Axogen
AXGN
$2.18B
$47.9M 12.19%
1,300,000
-140,000
-10% -$6.11M
2015 Q1
14 quarters
CDXS icon
2
Codexis
CDXS
$154M
$30M 7.64%
1,750,000
– –
2014 Q1
18 quarters
LOXO
3
DELISTED
Loxo Oncology, Inc
LOXO
$29.9M 7.61%
175,000
– –
2016 Q3
8 quarters
AMRN icon
4
Amarin Corp
AMRN
$254M
$26M 6.62%
80,000
-7,500
-9% -$566K
2017 Q4
3 quarters
BPMC icon
5
DELISTED
Blueprint Medicines
BPMC
$23.4M 5.96%
300,000
-50,000
-14% -$3.48M
2015 Q3
12 quarters
DCPH icon
6
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$16.3M 4.14%
420,000
– –
2018 Q1
2 quarters
PTE
7
DELISTED
PolarityTE, Inc. Common Stock
PTE
$14.6M 3.72%
30,600
-1,400
-4% -$807K
2018 Q2
1 quarter
VKTX icon
8
Viking Therapeutics
VKTX
$3.6B
$14.4M 3.66%
825,000
-375,000
-31% -$4.46M
2017 Q4
3 quarters
KYNB icon
9
Kyntra Bio
KYNB
$24.8M
$12.2M 3.09%
8,000
-6,400
-44% -$9.86M
2014 Q4
15 quarters
AGIO icon
10
Agios Pharmaceuticals
AGIO
$1.84B
$10M 2.55%
130,000
– –
2016 Q1
10 quarters
BOLD icon
11
DELISTED
Audentes Therapeutics, Inc
BOLD
$8.91M 2.27%
225,000
+35,000
+18% +$1.3M
2017 Q2
5 quarters
DNTH icon
12
Dianthus Therapeutics
DNTH
$4.56B
$8.71M 2.22%
45,313
+10,938
+32% +$2.3M
2018 Q2
1 quarter
PTCT icon
13
PTC Therapeutics
PTCT
$5.25B
$8.46M 2.15%
180,000
– –
2018 Q1
2 quarters
AMAG
14
DELISTED
AMAG Pharmaceuticals
AMAG
$8.4M 2.14%
420,000
– –
2018 Q2
1 quarter
SBBP
15
DELISTED
Strongbridge Biopharma plc.
SBBP
$8.39M 2.13%
1,730,000
-100,000
-5% -$512K
2016 Q4
7 quarters
SGMO icon
16
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$8.3M 2.11%
490,000
-15,000
-3% -$228K
2016 Q4
7 quarters
FENC icon
17
Fennec Pharmaceuticals
FENC
$376M
$8M 2.03%
975,000
+30,000
+3% +$278K
2017 Q4
3 quarters
VRDN icon
18
Viridian Therapeutics
VRDN
$2.07B
$7.79M 1.98%
93,047
+13,047
+16% +$1.23M
2018 Q2
1 quarter
CBAY icon
19
DELISTED
Cymabay Therapeutics
CBAY
$7.74M 1.97%
698,100
+600
+0.1% +$7.45K
2017 Q3
4 quarters
XENE icon
20
Xenon Pharmaceuticals
XENE
$3.47B
$7.01M 1.78%
+465,200
New +$5.39M
2018 Q3
0 quarters
APLS icon
21
DELISTED
Apellis Pharmaceuticals
APLS
$6.67M 1.7%
375,000
+110,000
+42% +$2.03M
2018 Q2
1 quarter
XNCR icon
22
Xencor
XNCR
$1.86B
$6.14M 1.56%
180,000
– –
2018 Q2
1 quarter
RARE icon
23
Ultragenyx Pharmaceutical
RARE
$1.51B
$6.11M 1.55%
80,000
– –
2017 Q4
3 quarters
XOMA icon
24
DELISTED
Xoma
XOMA
$5.62M 1.43%
320,000
-200
-0.1% -$4.01K
2017 Q1
6 quarters
OCUL icon
25
Ocular Therapeutix
OCUL
$1.66B
$5.5M 1.4%
800,000
-311,000
-28% -$1.95M
2018 Q1
2 quarters
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2018 Portfolio in Review

As of Q3 2018, Opaleye Management held 48 positions worth $393M, up 1.7% from $386M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Opaleye Management's Q3 2018 filing shows 12 new, 9 increased, 16 reduced and 1 closed positions. Its largest new stake was Xenon Pharmaceuticals: 465,200 shares worth $7.01M. The largest sale was Kyntra Bio, an estimated $9.86M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Opaleye Management's largest Q3 2018 buy was Xenon Pharmaceuticals: 465,200 shares worth $7.01M.
  • Opaleye Management added most to CTI BioPharma Corp. (DE) Common Stock in Q3 2018, an estimated $3.44M increase.
  • Opaleye Management's biggest Q3 2018 reduction was Kyntra Bio, cutting an estimated $9.86M.
  • Opaleye Management fully exited GridAI Technologies Corp in Q3 2018, selling an estimated $417K.
  • Opaleye Management's ten largest holdings make up 57% of its $393M portfolio in Q3 2018.
  • Opaleye Management opened 12 new positions and closed 1 in Q3 2018.
  • Opaleye Management's portfolio value rose 1.7% quarter-over-quarter to $393M.

Based on Opaleye Management's 13F filing for Q3 2018, filed 14 Nov 2018.